

Interview Summary

Application No.

10/582,385

Applicant(s)

SANTINI ET AL.

Examiner

MELISSA S. MERCIER

Art Unit

1615

All participants (applicant, applicant's representative, PTO personnel):

(1) MELISSA S. MERCIER.

(2) Carlos Azpuru.

(3) Mark Nuell (attorney of record)

(4) Antonia Machado (inventor)

Date of Interview: 11-10-09.

Type: a) ☐ Telephonic b) ☐ Video Conference
c) ☒ Personal [copy given to: 1) ☐ applicant 2) ☒ applicant's representative]

Exhibit shown or demonstration conducted: d) ☒ Yes e) ☐ No.

If Yes, brief description: Slide show

Claim(s) discussed: newly submitted claims 107-119

Identification of prior art discussed: US Pat 5,698,582

Agreement with respect to the claims f) ☐ was reached. g) ☐ was not reached. h) ☐ N/A.

Substance of Interview including description of the general nature of what was agreed to if an agreement was reached, or any other comments: _____

(A fuller description, if necessary, and a copy of the amendments which the examiner agreed would render the claims allowable, if available, must be attached. Also, where no copy of the amendments that would render the claims allowable is available, a summary thereof must be attached.)

THE FORMAL WRITTEN REPLY TO THE LAST OFFICE ACTION MUST INCLUDE THE SUBSTANCE OF THE INTERVIEW. (See MPEP Section 713.04). If a reply to the last Office action has already been filed, APPLICANT IS GIVEN A NON-EXTENDABLE PERIOD OF THE LONGER OF ONE MONTH OR THIRTY DAYS FROM THIS INTERVIEW DATE, OR THE MAILING DATE OF THIS INTERVIEW SUMMARY FORM, WHICHEVER IS LATER, TO FILE A STATEMENT OF THE SUBSTANCE OF THE INTERVIEW. See Summary of Record of Interview requirements on reverse side or on attached sheet.

Mr. Machado presented a slide show regarding the background of pharmaceutical stability-comparing alkaline, neutral, and acid conditions and their ability to be formulated in pharmaceutical formulations

Mr. Nuell was requested to provide written support for numerous terms within the new claims, such as "lower than 0.12% w/w water content"; "amorphous"; "11-100 mg/ml"; "free of ethanol"; additionally steps into the specification.
all attached.

Maria Santini

Mr. Machuga further discussed, ~~about~~ the slideshow, the weakening
of Bactair (US Patent 5,696,582); the pH of the composition
is not the underlying cause of the degradation.
Alcohols, water & alkalinity all contribute to the degradation
of the active agents.

Mr. Null was requested to provide a copy of the
presented slideshow in ~~the~~ ^{mem} his latest summary
_{11-16-09.}

applicant is requested to clarify the criticality
of the micelles discussed in the slideshow.